Literature DB >> 29436275

Predictors of Readmission and Reoperation in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism.

Ansley M Roche1,2, Jason A Brant3, Raymond L Chai1.   

Abstract

Objective Identify risk factors for 30-day reoperation and readmission after parathyroidectomy for primary hyperparathyroidism. Study Design Retrospective analysis of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database from 2012 through 2014. Subjects and Methods Patients undergoing parathyroidectomy and parathyroid reexploration for primary hyperparathyroidism. Univariate and multivariate analyses were conducted to determine risk factors for reoperation and readmission. Results Of the 9439 patients who underwent parathyroidectomy, 72 patients underwent 1 reoperation in the first 30 days after surgery, and 8 patients underwent 2 reoperations. The most common reasons were hematoma (25%) and persistent hyperparathyroidism (15.9%). Risk factors included smoking (odds ratio [OR], 1.86; 95% confidence interval [CI], 0.97-3.31), insulin-dependent diabetes (OR, 2.38; 95% CI, 1.02-4.86), and history of bleeding disorder (OR, 3.95; 95% CI, 1.48-8.79). In total, 182 (1.9%) patients were readmitted within 30 days of surgery; the most common cause was hypocalcemia (17.0%). Risk factors included operative time (hours) (OR, 1.3; 95% CI, 1.1-1.5), insulin-dependent diabetes mellitus (OR, 2.01; 95% CI, 1.2-3.3), dyspnea with moderate exertion (OR, 5.77; 95% CI, 0.86-14.67), and age (decade) (OR, 1.16; 95% CI, 1.02-1.32). Patients undergoing outpatient surgery were less likely to be readmitted (OR, 0.49; 95% CI, 0.35-0.69) or undergo reoperation (OR, 0.44; 95% CI, 0.27-0.73). Conclusions Thirty-day reoperation rate after parathyroidectomy was low and most commonly occurred due to hematoma. Risk factors for readmission were multifactorial and associated with perioperative factors, patient factors, and medical comorbidities. Preoperative counseling for patients at increased risk of readmission and reoperation may decrease these rates.

Entities:  

Keywords:  hypercalcemia; outcomes; parathyroidectomy; readmission; reexploration; reoperation

Mesh:

Year:  2018        PMID: 29436275     DOI: 10.1177/0194599818758019

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Association of Diabetes Mellitus With Postoperative Complications and Mortality After Non-Cardiac Surgery: A Meta-Analysis and Systematic Review.

Authors:  Xiaoying Zhang; Aisheng Hou; Jiangbei Cao; Yanhong Liu; Jingsheng Lou; Hao Li; Yulong Ma; Yuxiang Song; Weidong Mi; Jing Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

2.  The impact of patient age on practice patterns and outcomes for primary hyperparathyroidism.

Authors:  Whitney Sutton; Joseph K Canner; Jessica B Shank; Abbey L Fingeret; Shkala Karzai; Dorry L Segev; Jason D Prescott; Aarti Mathur
Journal:  Am J Surg       Date:  2022-03-19       Impact factor: 3.125

3.  Safety of parathyroidectomy in older vs. younger patients with primary hyperparathyroidism.

Authors:  Marlena Mueller; Fahim Ebrahimi; Emanuel Christ; Christian Andreas Nebiker; Philipp Schuetz; Beat Mueller; Alexander Kutz
Journal:  Endocr Connect       Date:  2021-10-11       Impact factor: 3.335

4.  Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism.

Authors:  Giuseppa Graceffa; Calogero Cipolla; Silvia Calagna; Silvia Contino; Giuseppina Melfa; Giuseppina Orlando; Riccardo Antonini; Alessandro Corigliano; Maria Pia Proclamà; Sergio Mazzola; Gianfranco Cocorullo; Gregorio Scerrino
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

Review 5.  Preoperative and Intraoperative Methods of Parathyroid Gland Localization and the Diagnosis of Parathyroid Adenomas.

Authors:  Jacek Baj; Robert Sitarz; Marek Łokaj; Alicja Forma; Marcin Czeczelewski; Amr Maani; Gabriella Garruti
Journal:  Molecules       Date:  2020-04-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.